.
Executive Summary
– Development of Novel Nerve Repair & Regeneration Products
ReNerve is developing a comprehensive portfolio of products for the nerve repair and regeneration markets and related surgical procedures, with clearly defined commercial demand.
Expanding Product Portfolio
4 product ranges expected on market by year end (CY’25), with more in development and research.
– Strong Sales & Distribution Presence
ReNerve has established logistics, warehouse and invoicing infrastructure with a strong focus on building a sales distribution network for all products in the US.
– Global Expansion & Commercialisation
Successful ongoing expansion within the first year of ASX listing into Ex-US markets in Asia, India, The Middle East, and The Americas.
– Clinical & Professional Validation
Improved patient outcomes for post-surgical measures of pain and surgery satisfaction, as well as proven ease of use for surgeons.
Continued Market Engagement
Three new products ranges into the US market this CY
• Dermal and amniotic products now in market and launched
• Have achieved first dermal sale
• First conduit product by year end
• Provides sales teams a range of four products by year end, expected to aid sales of NervAlign nerve cuff and grow company revenue
Working with distributors for additional approvals
• Sales infrastructure suitable for all products
• Indian and other Asian countries in process
US Direct ReNerve sales
• Small team in the US
• Supporting the 21 distributors
• ReNerve team to ‘hold the hands’ of
distributors for new products and initial sales
